dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
Published 4 weeks ago • 32 plays • Length 3:28Download video MP4
Download video MP3
Similar videos
-
1:18
dr rini on a biomarker analysis of keynote-426 using subtype clustering rcc
-
1:34
dr. rini on pembrolizumab plus axitinib in rcc
-
1:59
dr rini on the background of a biomarker analysis of keynote-426 in rcc
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
8:07
tki/io comparison: lenvatinib/pembrolizumab vs cabozantinib/nivolumab vs axitinib/pembrolizumab
-
16:27
finding lung cancer earlier with ronnie andrews oncocyte
-
0:49
dr. rini describes hypertension as a biomarker in rcc
-
1:03
dr. rini on managing the toxicity of pembrolizumab plus axitinib in mrcc
-
0:53
dr. rini on standards of care for advanced rcc
-
0:38
dr. rini explains the axitinib integration process
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc
-
2:06
dr. rini discusses tivozanib in advanced rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
1:17
dr. vaishampayan on axitinib plus pembrolizumab in advanced rcc
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
1:12
dr. rini describes axitinib's and sorafenib's side effects
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
0:43
dr. rini on adjuvant immunotherapy in renal cell carcinoma
-
1:40
dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
-
0:43
dr. rini discusses the vegf targeted agent axitinib